Skip to main content
Journal ArticleOPEN ACCESS

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

  • Bakkour W
  • Coulson I
Dermatology and Therapy (2012) 2(1)
DOI: 10.1007/s13555-012-0003-9
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

INTRODUCTION: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established.CASE REPORT: The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma.CONCLUSION: This is the first case report of cutaneous side effects of GA101.

Cite

CITATION STYLE

APA

Bakkour, W., & Coulson, I. H. (2012). GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption. Dermatology and Therapy, 2(1). https://doi.org/10.1007/s13555-012-0003-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free